Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. gliomark

GLIOMARK SIGNED

Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 GLIOMARK project word cloud

Explore the words cloud of the GLIOMARK project. It provides you a very rough idea of what is the project "GLIOMARK" about.

therapies    validated    invasive    subsequent    emission    safe    poor    glioma    containing    distinguish    tetrofosmin    diagnostic    technique    pertechnetate    tlr    orphan    reproducibility    preparation    diagnostics    unable    spect    outcome    combination    exclude    gliotect    specificity    grading    blood    designation    innovative    gliomark    clinically    confirmation    accomplished    magnetic    detect    hence    reconstituted    mography    grade    biomarker    objective    kit    niche    permeability    reliability    vivo    sensitivity    diagnosis    replace    latter    reliably    speciality    resonance    chemical    computer    diagnose    sme    disease    biopsies    rare    differential    aggregated    first    validate    prognosis    proactina    opportunity    point    affordable    global    aggressiveness    imaging    instructions    expensive    gliomas    tumor    yield    lifted    hospitals    barrier    greek    guarantee    bbb    single    selling    99mtc    exclusivity    tolerated    market    ttf    brain    handling    radiotracer    leader    assesses    sale    photon    fast    diseases    tomography    approval   

Project "GLIOMARK" data sheet

The following table provides information about the project.

Coordinator		 CONSULTECH TECHNOLOGIEBERATUNG GMBH 

Organization address
address: MORGENSTERNSTRASSE 24
city: BERLIN
postcode: 12207
website: www.consultech.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.gliomark.eu
 Total cost 4˙705˙344 €
 EC max contribution 4˙705˙344 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSULTECH TECHNOLOGIEBERATUNG GMBH DE (BERLIN) coordinator 3˙167˙094.00
2    PRO-ACTINA CHIMIKI TECHNOLOGIA ANONIMI ETAIRIA EL (MAROUSI ATHENS) participant 1˙538˙250.00

Map

 Project objective

Objective of GLIOMARK is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis and grading of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer To-mography (SPECT). The outcome of GLIOMARK is GlioTect, a diagnostic kit containing handling/diagnostic instructions and tetrofosmin. The latter has to be reconstituted with 99mTc pertechnetate to yield TTF, which will be used in combination with SPECT. Often computer tomography or magnetic resonance imaging are unable to detect low-grade gliomas or distinguish glioma from other diseases. Hence, brain biopsies are necessary for confirmation of diagnosis and grading of gliomas. GlioTect with TTF/SPECT enables reliable, fast differential diagnosis and grading of gliomas as non-invasive method. This has an immediate impact on the type and aggressiveness of subsequent therapies. Gliomas are recognized as a rare tumor disease with poor prognosis and orphan diagnostic designation for GlioTect will guarantee 10 years of market exclusivity upon approval. ProActina, a Greek chemical-speciality SME having identified this innovative niche market opportunity could become global market leader in glioma diagnostics. Development is at TLR level 6-7 and will be lifted to 9. Expected market application is the sale of GlioTect for preparation of TTF for use with SPECT. End users are hospitals that use the kit to reliably diagnose or exclude gliomas without the need for expensive equipment. Taken together, the aggregated unique selling point of SPECT in combination with TTF (generated by means of GlioTect) is the first ever and only glioma diagnostic, which assesses a clinically validated glioma biomarker, has high reliability, reproducibility, sensitivity, as well as specificity, which is used to replace an invasive method, is safe, well tolerated, widely available and more affordable

 Deliverables

List of deliverables.
Set up project homepage Websites, patent fillings, videos etc. 2019-07-25 13:49:19

Take a look to the deliverables list in detail:  detailed list of GLIOMARK deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOMARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOMARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More